Citi Cuts Stryker (SYK) PT, Maintains Buy Amid Leadership Changes

Group 1 - Stryker Corporation (NYSE:SYK) is recognized as a leading healthcare AI stock, with Citi adjusting its price target from $455 to $420 while maintaining a Buy rating [1][2] - The company declared a quarterly dividend of $0.88 per share, which is a 4.8% increase from the previous dividend paid in October 2025, resulting in an annualized dividend of $3.52 per share [2] - Stryker appointed Spencer Stiles as President and Chief Operating Officer, effective January 1, 2026, who will oversee global businesses and corporate strategy [3] - Dylan Crotty will be promoted to Group President of Orthopaedics, succeeding Stiles, and is noted for his operational leadership [4] Group 2 - Stryker designs and manufactures medical technologies in orthopedics, surgical equipment, and neurotechnology, utilizing AI in surgical robotics, predictive analytics, enhanced imaging, inventory management, and remote monitoring [5]